Analysed NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) News Sources
NeuroOne(R) Advances Brain Drug Delivery Platform Through Collaboration With University of Minnesota
15-04-2026
yahoo.com
NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq Compliance
14-04-2026
yahoo.com
NeuroOne(R) Medical Technologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026
yahoo.com
NeuroOne(R) Successfully Completes Limited Market Release of OneRF(R) Trigeminal Nerve Ablation System
26-03-2026
yahoo.com
NeuroOne(R) Announces Publication of Clinical Experience With Its OneRF(R) sEEG-Guided Radiofrequency Ablation Technology
17-03-2026
yahoo.com
NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern Time
11-03-2026
yahoo.com
NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million Shares
03-03-2026
yahoo.com
NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time
26-02-2026
yahoo.com
What is the current price of NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ)?
The current price of NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) is $5.05.
NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) since the previous trading day is $0.07.
NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) since the previous trading day is 1.4056%.
What is the most recent average sentiment score for NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ)?
The most recent average sentiment score for NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ)?
The most recent sentiment for NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ) is .
SEC-8K** Filing Available For NEUROONE MEDICAL TECHNOLOGIE (NMTC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.